Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02378155
Other study ID # AF I
Secondary ID
Status Completed
Phase N/A
First received December 17, 2014
Last updated August 18, 2015
Start date February 2015

Study information

Verified date August 2015
Source Hasselt University
Contact n/a
Is FDA regulated No
Health authority Belgium: Ethics Committee
Study type Interventional

Clinical Trial Summary

Near infrared spectroscopy (NIRS) is a technique that measures regional cerebral oxygenation in a non-invasive manner. Through the use of near infrared light, the difference between oxygenated and deoxygenated hemoglobin can be measured. By applying the Lambert-Beer law, a numeric result can be calculated.

Since atrial fibrillation (AF) has been linked with an increased risk for the development of neurocognitive deficits, a longer period of AF might be associated with a higher risk for neurocognitive deficits.

It is hypothesized that there is an increase in the regional cerebral oxygen saturation (rSO2) of patients with paroxysmal or persistent AF after successful cardioversion.


Description:

Written informed consent by the patient is asked before cardioversion and participation in the study. Patient anamnesis is assessed by standardized questionnaire.

Patients perform several standardised neurocognitive tests to obtain a general view on the neurocognitive status (auditory verbal learning test, mini-mental state examination, trail making A and B, digit-symbol coding and RAND 36 Health Survey).

Cerebral oxygenation is observed during cardioversion by means of the SenSmart Model X-100 (Nonin). Additional parameters (pulse oximetry, cardiac output, arterial blood pressure, 6-lead electrocardiography (ECG), left ventricular ejection fraction) are recorded. All measurements are performed non-invasively. Patients receive standard treatment following the clinical guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- older than 18 years and able to give informed consent

- diagnosis of paroxysmal or persistent atrial fibrillation

- scheduled for electrical cardioversion or atrial fibrillation development in the first days after cardiac surgery followed by pharmacological treatment with amiodarone

- Dutch speaking

Exclusion Criteria:

- younger than 18 years or not able to give informed consent

- diagnosis of permanent atrial fibrillation

- atrial fibrillation with thrombus in left atrial appendage

- chronic obstructive pulmonary disease GOLD class 3 or 4

- airway manipulation during cardioversion

- pregnant women

- medical history of cerebrovascular accident or brain injury

- medical history of cardiopulmonary resuscitation

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms

  • Atrial Fibrillation
  • Electrical Cardioversion of Atrial Fibrillation
  • Pharmacological Cardioversion of Atrial Fibrillation

Intervention

Device:
SenSmart Model X-100, Nonin Medical
Device to measure cerebral tissue oxygen saturation

Locations

Country Name City State
Belgium Ziekenhuis Oost-Limburg Genk Limburg

Sponsors (1)

Lead Sponsor Collaborator
Hasselt University

Country where clinical trial is conducted

Belgium, 

References & Publications (2)

Pellicer A, Bravo Mdel C. Near-infrared spectroscopy: a methodology-focused review. Semin Fetal Neonatal Med. 2011 Feb;16(1):42-9. doi: 10.1016/j.siny.2010.05.003. Epub 2010 Jun 26. Review. — View Citation

Wutzler A, Nee J, Boldt LH, Kühnle Y, Gräser S, Schröder T, Haverkamp W, Storm C. Improvement of cerebral oxygen saturation after successful electrical cardioversion of atrial fibrillation. Europace. 2014 Feb;16(2):189-94. doi: 10.1093/europace/eut246. Epub 2013 Jul 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Measure the cerebral saturation changes in response to electrical/pharmacological cardioversion 6 months No
Secondary Measure the time for recuperation of cerebral saturation after a period of decreased cerebral saturation 6 months No
Secondary Relate the responses of cerebral saturation, regional saturation, pulse oximetry and blood pressure with each other 6 months No
Secondary Compare the changes in cerebral oxygen saturation with the left ventricular ejection fraction 6 months No
Secondary Perform neuropsychological tests before and after electrical/pharmacological cardioversion 6 months No
Secondary Compare the response of the cerebral/regional saturation with the effects on the neurocognitive status 6 months No
Secondary Compare the response of the pulse oximetry with the effects on the neurocognitive status 6 months No
Secondary Compare the response of the blood pressure with the effects on the neurocognitive status 6 months No